Bim and Mcl-1 exert key roles in regulating JAK2<sup>V617F </sup>cell survival
<p>Abstract</p> <p>Background</p> <p>The JAK2<sup>V617F </sup>mutation plays a major role in the pathogenesis of myeloproliferative neoplasms and is found in the vast majority of patients suffering from polycythemia vera and in roughly every second patient s...
Main Authors: | Guthy Daniel A, Andraos Rita, Qian Zhiyan, Rubert Joëlle, Radimerski Thomas |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-01-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/11/24 |
Similar Items
-
Immunoproteasome Genes Are Modulated in CD34<sup>+</sup> JAK2<sup>V617F</sup> Mutated Cells from Primary Myelofibrosis Patients
by: Michelino Di Rosa, et al.
Published: (2020-04-01) -
JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL.
by: Jun Guo, et al.
Published: (2015-01-01) -
Efficacy and Safety of [<sup>225</sup>Ac]Ac-PSMA-617 Augmented [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis
by: Florian Rosar, et al.
Published: (2021-05-01) -
Value of Combined PET Imaging with [<sup>18</sup>F]FDG and [<sup>68</sup>Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [<sup>177</sup>Lu]Lu-PSMA-617 RLT
by: Fadi Khreish, et al.
Published: (2021-08-01) -
A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression.
by: Emilie A Chapeau, et al.
Published: (2019-01-01)